Skin biology and ageing

Ewan A Langan^{1

2}, George W M Millington^{3

4}

Affiliations

Editorial

Ewan A Langan et al. Skin Health Dis. 2023.

. 2023 Jun 11;3(4):e258.

doi: 10.1002/ski2.258. eCollection 2023 Aug.

Ewan A Langan^{1

2}, George W M Millington^{3

4}

No abstract available

Conflict of interest statement

Ewan A. Langan is the Editor in Chief of Skin Health and Disease. George W. M. Millington is the Deputy Editor of Skin Health and Disease.

1. Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, et al. Treatment of plaque psoriasis with deucravacitinib (POETYK PSO‐2 study): a plain language summary. Immunotherapy. 2023. Epub ahead of print. PMID: 37150956. 10.2217/imt-2023-0062 - DOI - PubMed
1. Chovatiya R, Paller AS. JAK inhibitors in the treatment of atopic dermatitis. J Allergy Clin Immunol. 2021;148(4):927–40. 10.1016/j.jaci.2021.08.009 - DOI - PMC - PubMed
1. Kwon O, Senna MM, Sinclair R, Ito T, Dutronc Y, Lin CY, et al. Efficacy and safety of baricitinib in patients with severe alopecia areata over 52 Weeks of continuous therapy in two phase III trials (BRAVE‐AA1 and BRAVE‐AA2). Am J Clin Dermatol. 2023;24(3):443–51. 10.1007/s40257-023-00764-w - DOI - PMC - PubMed
1. Hamzavi I, Rosmarin D, Harris JE, Pandya AG, Lebwohl M, Gottlieb AB, et al. Efficacy of ruxolitinib cream in vitiligo by patient characteristics and affected body areas: descriptive subgroup analyses from a phase 2, randomized, double‐blind trial. J Am Acad Dermatol. 2022;86(6):1398–401. 10.1016/j.jaad.2021.05.047 - DOI - PubMed
1. Blauvelt A, Kempers S, Lain E, Schlesinger T, Tyring S, Forman S, et al. Phase 3 tirbanibulin for actinic keratosis group. Phase 3 trials of tirbanibulin ointment for actinic keratosis. N Engl J Med. 2021;384(6):512–20. 10.1056/nejmoa2024040 - DOI - PubMed